glioma glioma a glioma is a type of tumor that starts in the glial cells of the brain or the spine. gliomas comprise about 30 percent of all brain tumors and central nervous system tumours, and 80 percent of all malignant brain tumours. gliomaglioma in the left parietal lobe (brain ct scan), who grade 2specialtyoncology signs and symptoms symptoms of gliomas depend on which part of the central nervous system is affected. a brain glioma can cause headaches, vomiting, seizures, and cranial nerve disorders as a result of increased intracranial pressure. a glioma of the optic nerve can cause vision loss. spinal cord gliomas can cause pain, weakness, or numbness in the extremities. gliomas do not usually metastasize by the bloodstream, but they can spread via the cerebrospinal fluid and cause "drop metastases" to the spinal cord. complex visual hallucinations have been described as a symptom of low-grade glioma. a child who has a subacute disorder of the central nervous system that produces cranial nerve abnormalities (especially of cranial nerve vii and the lower bulbar nerves), long-tract signs, unsteady gait secondary to spasticity, and some behavioral changes is most likely to have a pontine glioma. causes hereditary disorders the exact causes of gliomas are not known. hereditary disorders such as neurofibromatoses (type 1 and type 2) and tuberous sclerosis complex are known to predispose to their development. different oncogenes can cooperate in the development of gliomas. diet some studies of diet and vitamin supplementation appear to point out that dietary n-nitroso compounds may affect the risk of both childhood and adult brain tumors. researchers have observed in some studies that brain tumor patients (or their mothers) have generally consumed more cured foods (also known as curing) than control groups. recently, drs. lee, wrensch and others found that adults with glioma were more likely to consume diets high in cured foods and low in vitamin c-rich fruits and vegetables, and to consume diets high in nitrites and low in vitamin c. the effect was more pronounced in men than women. however, the pattern of increased risk with increased consumption of cured foods, and decreased risk with greater consumption of fruits, vegetables, and antioxidant vitamins is compatible with other cancer studies that show increased consumption of vegetables and possibly of fruits is associated with decreased cancer risk. radiation a link between gliomas and electromagnetic radiation from cell phones has not been conclusively proven. it was considered possible, though several large studies have found no conclusive evidence, as summarized by the nih's national cancer institute review of the topic and its numerous citations, and the fcc. however, further research is still being pursued to obtain more robust evidence and verify that there is no relationship (the nih's national institute of environmental health sciences most recent press release discussed an ongoing study showing mildly positive results, although it appears there may have been issues with the control group dying prematurely). infection with cytomegalovirus some studies have reported that glioblastomas are infected with cytomegalovirus, with suggestions that this may speed the development of tumors. however, this is a controversial opinion, with recent in-depth studies failing to find an association between viral infection and glioma growth. there is also evidence that previous studies may have been impacted by false-positive antibody staining artifacts. other causes though some studies have shown that farmers have higher rates of gliomas compared to the general population, exposure to farm animals or manure is not associated with glioma. later studies have not found an association between farming and gliomas; similar conflicting data concerns teachers and glioma. more consistent data show that architects, surveyors, retail workers, butchers, and engineers have higher rates of gliomas. most studies have found that pesticide exposure is probably not a cause of glioma, though a minority of studies have found an association. inherited polymorphisms of the dna repair genes germ-line (inherited) polymorphisms of the dna repair genes ercc1, ercc2 (xpd) and xrcc1 increase the risk of glioma. this indicates that altered or deficient repair of dna damage contributes to the formation of gliomas. dna damages are a likely major primary cause of progression to cancer in general. excess dna damages can give rise to mutations through translesion synthesis. furthermore, incomplete dna repair can give rise to epigenetic alterations or epimutations. such mutations and epimutations may provide a cell with a proliferative advantage which can then, by a process of natural selection, lead to progression to cancer. epigenetic repression of dna repair genes is often found in progression to sporadic glioblastoma. for instance, methylation of the dna repair gene mgmt promoter was observed in 51% to 66% of glioblastoma specimens. in addition, in some glioblastomas, the mgmt protein is deficient due to another type of epigenetic alteration. mgmt protein expression may also be reduced due to increased levels of a microrna that inhibits the ability of the mgmt messenger rna to produce the mgmt protein. zhang et al. found, in the glioblastomas without methylated mgmt promoters, that the level of microrna mir-181d is inversely correlated with protein expression of mgmt and that the direct target of mir-181d is the mgmt mrna 3'utr (the three prime untranslated region of mgmt messenger rna). epigenetic reductions in expression of another dna repair protein, ercc1, were found in an assortment of 32 gliomas. for 17 of the 32 (53%) of the gliomas tested, ercc1 protein expression was reduced or absent. in the case of 12 gliomas (37.5%) this reduction was due to methylation of the ercc1 promoter. for the other 5 gliomas with reduced ercc1 protein expression, the reduction could have been due to epigenetic alterations in micrornas that affect ercc1 expression. when expression of dna repair genes is reduced, dna damages accumulate in cells at a higher than normal level, and such excess damages cause increased frequencies of mutation. mutations in gliomas frequently occur in either isocitrate dehydrogenase (idh) 1 or 2 genes. one of these mutations (mostly in idh1) occurs in about 80% of low grade gliomas and secondary high-grade gliomas. wang et al. pointed out that idh1 and idh2 mutant cells produce an excess metabolic intermediate, 2-hydroxyglutarate, which binds to catalytic sites in key enzymes that are important in altering histone and dna promoter methylation. thus, mutations in idh1 and idh2 generate a "dna cpg island methylator phenotype or cimp" that causes promoter hypermethylation and concomitant silencing of tumor suppressor genes such as dna repair genes mgmt and ercc1. on the other hand, cohen et al. and molenaar et al. pointed out that mutations in idh1 or idh2 can cause increased oxidative stress. increased oxidative damage to dna could be mutagenic. this is supported by an increased number of dna double-strand breaks in idh1-mutated glioma cells. thus, idh1 or idh2 mutations act as driver mutations in glioma carcinogenesis, though it is not clear by which role they are primarily acting. a study, involving 51 patients with brain gliomas who had two or more biopsies over time, showed that mutation in the idh1 gene occurred prior to the occurrence of a p53 mutation or a 1p/19q loss of heterozygosity, indicating that an idh1 mutation is an early driver mutation. pathophysiology high-grade gliomas are highly vascular tumors and have a tendency to infiltrate diffusely. they have extensive areas of necrosis and hypoxia. often, tumor growth causes a breakdown of the blood–brain barrier in the vicinity of the tumor. as a rule, high-grade gliomas almost always grow back even after complete surgical excision, so are commonly called recurrent cancer of the brain. conversely, low-grade gliomas grow slowly, often over many years, and can be followed without treatment unless they grow and cause symptoms. several acquired (not inherited) genetic mutations have been found in gliomas. tumor suppressor protein 53 (p53) is mutated early in the disease. p53 is the "guardian of the genome", which, during dna and cell duplication, makes sure the dna is copied correctly and destroys the cell (apoptosis) if the dna is mutated and cannot be fixed. when p53 itself is mutated, other mutations can survive. phosphatase and tensin homolog (pten), another tumor suppressor gene, is itself lost or mutated. epidermal growth factor receptor, a growth factor that normally stimulates cells to divide, is amplified and stimulates cells to divide too much. together, these mutations lead to cells dividing uncontrollably, a hallmark of cancer. in 2009, mutations in idh1 and idh2 were found to be part of the mechanism and associated with a less favorable prognosis. diagnosis classification gliomas are classified by cell type, by grade, and by location. by type of cell gliomas are named according to the specific type of cell with which they share histological features, but not necessarily from which they originate. the main types of glioma are: ependymomas: ependymal cells astrocytomas: astrocytes (glioblastoma multiforme is a malignant astrocytoma and the most common primary brain tumor among adults). oligodendrogliomas: oligodendrocytes brainstem glioma: develop in the brain stem optic nerve glioma: develop in or around the optic nerve mixed gliomas, such as oligoastrocytomas, contain cells from different types of glia by grade gliomas are further categorised according to their grade, which is determined by pathologic evaluation of the tumor. the neuropathological evaluation and diagnostics of brain tumor specimens is performed according to who classification of tumours of the central nervous system. low-grade brain glioma in a 28-year-old male. (taken on 10 july 2007) biologically benign gliomas are comparatively low risk and can be removed surgically depending on their location low-grade gliomas are well-differentiated (not anaplastic); these tend to exhibit benign tendencies and portend a better prognosis for the patient. however, they have a uniform rate of recurrence and increase in grade over time so should be classified as malignant. high-grade gliomas are undifferentiated or anaplastic; these are malignant and carry a worse prognosis. of numerous grading systems in use, the most common is the world health organization (who) grading system for astrocytoma, under which tumors are graded from i (least advanced disease—best prognosis) to iv (most advanced disease—worst prognosis). by location gliomas can be classified according to whether they are above or below a membrane in the brain called the tentorium. the tentorium separates the cerebrum (above) from the cerebellum (below). the supratentorial is above the tentorium, in the cerebrum, and mostly found in adults (70%). the infratentorial is below the tentorium, in the cerebellum, and mostly found in children (70%). the pontine tumors are located in the pons of the brainstem. the brainstem has three parts (pons, midbrain, and medulla); the pons controls critical functions such as breathing, making surgery on these extremely dangerous. treatment treatment for brain gliomas depends on the location, the cell type, and the grade of malignancy. current treatment options include surgical removal, radiation (radiation therapy), and chemotherapy. in some cases, tumour treating fields (alternating electric field therapy), a recently developed technology, may be used. often, treatment is a combined approach, using surgery, radiation therapy, and chemotherapy. for many, treatment consists of just surgery, or even "watchful waiting" (waiting to see when an intervention is justified due to tumour progression). doctors carefully balance the specifics of the patient's tumour and the downsides of intervention, since there can be significant side effects from medical intervention. radiation and chemotherapy remain the mainstays of treatment beyond surgery. radiation therapy is delivered in the form of external beam radiation or the stereotactic approach using radiosurgery. temozolomide is a common chemotherapy drug which can be administered easily in an outpatient setting and is able to cross the blood–brain barrier effectively. there are a wide variety of novel treatments currently being tested in clinical trials, ranging from idh inhibitors like ivosidenib, to the recently approved dendritic cell-based cancer vaccine approach. treatment using immunotherapy is another promising research path that may help treat glioma in the near future. experimental therapies like oncolytic viruses have shown potential therapeutic benefits in clinical trials (but have not been approved for use in non-experimental settings). refractory disease for recurrent high-grade glioblastoma, recent studies have taken advantage of angiogenic blockers such as bevacizumab in combination with conventional chemotherapy, with encouraging results. relative effectiveness a 2017 meta-analysis compared surgical resection versus biopsy as the initial surgical management option for a person with a low-grade glioma. results show the evidence is insufficient to make a reliable decision. the relative effectiveness of surgical resection compared to